Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. [electronic resource]
Producer: 20070313Description: 1141-9 p. digitalISSN:- 0020-7136
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters -- analysis
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Benzamides
- Cell Line, Tumor
- Drug Evaluation, Preclinical
- Humans
- Imatinib Mesylate
- Mice
- Mice, Nude
- Neoplasm Proteins -- analysis
- Piperazines -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins c-kit -- analysis
- Pyrimidines -- therapeutic use
- RNA, Messenger -- analysis
- Receptors, Platelet-Derived Growth Factor -- analysis
- Rhabdomyosarcoma -- drug therapy
- Topotecan -- therapeutic use
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.